Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Kenju Ando
Observed names:
K. Ando,
アンドウ, ケンジュ
Institutions:
National Center for Global Health and Medicine,
Japan Institute for Health Security
Observed institutions:
Mochida Pharmaceutical (Japan),
Juntendo University,
Shizuoka Cancer Center,
National Center for Global Health and Medicine,
Taiho Pharmaceutical (Japan),
Hiroshima University Hospital,
Nippon Shinyaku (Japan),
Japan Institute for Health Security,
Nagoya University
show all 9
ORCID:
0009-0007-6645-2674
Observed ORCID:
0009-0007-6645-2674
OpenAlex ID:
A5034568552
Meflin-Positive Cancer-Associated Fibroblasts Inhibit Pancreatic Carcinogenesis
2019
·
Yasuyuki Mizutani
, Hiroki Kobayashi
, et al.
·
Cancer Research
·
378
PDF
Identification of Meflin as a Potential Marker for Mesenchymal Stromal Cells
2016
·
Keiko Maeda
, Atsushi Enomoto
, et al.
·
Scientific Reports
·
103
PDF
Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer
2022
·
Kaito Mimura
, Akihiko Shimomura
, et al.
·
Gynecologic Oncology Reports
·
14
PDF
The efficacy and safety of anamorelin among patients with diabetes
2024
·
Kenju Ando
, Tateaki Naito
, et al.
·
International Journal of Clinical Oncology
·
6
Impact of HIV status on prognosis of malignancies among people living with HIV in Japan
2024
·
Kenju Ando
, Akihiko Shimomura
, et al.
·
Cancer
·
4
Continuous glucose monitoring–guided management of capivasertib‐associated hyperglycemia: A case series of three patients
2026
·
Hiroki Okumura
, Ryotaro Bouchi
, et al.
·
Journal of Diabetes Investigation
·
2
A Case of Recurrent Ovarian Cancer and Therapy-Related Acute Myeloid Leukemia Treated with Azacitidine
2021
·
Kenju Ando
, Akihiko Shimomura
, et al.
·
Case Reports in Oncology
·
2
Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection
2026
·
Risako Komata
, Kenju Ando
, et al.
·
Journal of Clinical Oncology
·
1
Optimizing the adjuvant chemotherapy for HER2-positive early breast cancer
2025
·
Kenju Ando
, Akihiko Shimomura
·
AME Clinical Trials Review
·
1
Rethinking ribociclib: revisiting dosing, duration, and the N0 high-risk dilemma in the NATALEE trial
2025
·
A. Mimura
, A. Shimomura
, et al.
·
Annals of Oncology
·
1
Efficacy of subsequent treatment for unresectable locally-advanced non-small cell lung cancer after relapse of concurrent chemoradiotherapy with durvalumab consolidation therapy: A single-center retrospective study
2024
·
Yuichiro Nishibori
, Hirotsugu Kenmotsu
, et al.
·
Cancer Treatment and Research Communications
·
1
What Is the Optimal Model to Estimate the Benefits of Chemotherapy in Patients With Hormone Receptor–Positive, HER2-Negative, Node-Negative Breast Cancer?
2021
·
Kenju Ando
, Akihiko Shimomura
, et al.
·
Journal of Clinical Oncology
·
1
HIV management during the final 90 days of life in people living with HIV and advanced cancer: a retrospective cohort study
2026
·
Kenju Ando
, Akihiko Shimomura
, et al.
·
BMC Palliative Care
140eP Clinical characteristics of T4 Stage IV breast cancer: A single-center retrospective study from Tokyo
2025
·
K. Ando
, A. Shimomura
, et al.
·
Annals of Oncology
Deterioration of performance status before administration of chemotherapy as a prognostic factor in untreated advanced non-small cell lung cancer
2025
·
Kenju Ando
, Hirotsugu Kenmotsu
, et al.
·
Cancer Treatment and Research Communications
Supplementary Data from Meflin-Positive Cancer-Associated Fibroblasts Inhibit Pancreatic Carcinogenesis
2023
·
Yasuyuki Mizutani
, Hiroki Kobayashi
, et al.
Data from Meflin-Positive Cancer-Associated Fibroblasts Inhibit Pancreatic Carcinogenesis
2023
·
Yasuyuki Mizutani
, Hiroki Kobayashi
, et al.
Show more works
View as search
Works count:
18
Citation count:
514
H-index:
4
I10-index:
3
Year
Topic
Type